Retrospective Analysis for S-l and Second-line Chemotherapy for Stage IV Gastric Cancer

摘要

We retrospectively reviewed the clinical records of 102 patients of Stage IV gastric cancer from 1996 to 2003. Among 102 patients, 61 patients were treated with S-l alone as a first-line, and 41 patients received other chemotherapy (control group). No difference was found in clinical parameters between the two groups. Median survival of time was 449 days for the S-l-treated group and 236 days for the control group. In subset analysis, a better survival was demonstrated in patients who had one metastatic site or given second line. It was suggested that for the patients with two or more metastatic sites, first line combination therapy containing S-l might be required to improve their survival. The combination therapy for the patients with more than two sites of metastasis should be studied.